{"id":"https://openalex.org/W2528056154","doi":null,"title":"Naltrexone as treatment for amphetaminism","display_name":"Naltrexone as treatment for amphetaminism","alternate_titles":[],"publication_year":2009,"publication_date":"2009-04-20","ids":{"openalex":"https://openalex.org/W2528056154","mag":"2528056154"},"language":"en","primary_location":{"id":"mag:2528056154","doi":null,"is_oa":false,"landing_page_url":"http://scnp.org/journal/index.php/SCNP/article/view/85","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2528056154"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050667070","display_name":"Johan Franck","orcid":"https://orcid.org/0000-0002-4355-1967","observed_orcids":["https://orcid.org/0000-0002-4355-1967"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Johan Franck","raw_affiliation_strings":["Karolinska Institutet"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karolinska Institutet","institution_ids":["https://openalex.org/I28166907"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5050667070"],"corresponding_institution_ids":["https://openalex.org/I28166907"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"1","first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9384999871253967,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9384999871253967,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.05000000074505806,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.008100000210106373,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/naltrexone","display_name":"naltrexone","score":1.0},{"id":"https://openalex.org/keywords/amphetamine-dependence","display_name":"amphetamine dependence","score":0.9990000128746033},{"id":"https://openalex.org/keywords/opioid-antagonists","display_name":"opioid antagonists","score":0.7789999842643738},{"id":"https://openalex.org/keywords/drug-seeking-behavior","display_name":"drug-seeking behavior","score":0.5979999899864197},{"id":"https://openalex.org/keywords/abstinence","display_name":"abstinence","score":0.7070000171661377},{"id":"https://openalex.org/keywords/stimulant-dependence","display_name":"stimulant use disorder","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C2777972943","wikidata":"https://www.wikidata.org/wiki/Q409587","display_name":"Naltrexone","level":4,"score":0.9564275741577148},{"id":"https://openalex.org/C2777193897","wikidata":"https://www.wikidata.org/wiki/Q179452","display_name":"Amphetamine","level":3,"score":0.8355210423469543},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7718299031257629},{"id":"https://openalex.org/C2780687700","wikidata":"https://www.wikidata.org/wiki/Q210978","display_name":"Abstinence","level":2,"score":0.6820447444915771},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49812865257263184},{"id":"https://openalex.org/C2775962371","wikidata":"https://www.wikidata.org/wiki/Q908096","display_name":"Opioid antagonist","level":5,"score":0.43045222759246826},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4247598648071289},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.40920189023017883},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.40185537934303284},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38325127959251404},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3522583842277527},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3289172947406769},{"id":"https://openalex.org/C2778750930","wikidata":"https://www.wikidata.org/wiki/Q4540629","display_name":"(+)-Naloxone","level":4,"score":0.1323697865009308},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.06455850601196289},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.057874202728271484},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2528056154","doi":null,"is_oa":false,"landing_page_url":"http://scnp.org/journal/index.php/SCNP/article/view/85","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2116763568","https://openalex.org/W1889980870","https://openalex.org/W2090627492","https://openalex.org/W2321872756","https://openalex.org/W2736869086","https://openalex.org/W2605146310","https://openalex.org/W2116696440","https://openalex.org/W1990823468","https://openalex.org/W2040116927","https://openalex.org/W4376617051"],"abstract_inverted_index":{"T":[0],"here":[1],"is":[2],"no":[3],"approved":[4],"medication":[5,123],"for":[6,104,140],"the":[7,13,66,118,156,180,195],"treatment":[8],"of":[9,16,19,37,51,69,81,86,159,167,188,202,206],"amphetamine":[10,52,70,76,105,151,161,189],"dependence":[11,106],"despite":[12],"widespread":[14],"abuse":[15],"this":[17],"type":[18],"psychostimulant":[20],"drugs.":[21],"Animal":[22],"studies":[23],"have":[24,40],"shown":[25,42],"that":[26,43,179],"naltrexone,":[27],"a":[28,94,184],"non-selective":[29],"opioid":[30],"receptor":[31],"antagonist,":[32],"reduces":[33,45],"certain":[34],"behavioural":[35],"effects":[36,68],"amphetamine.":[38],"We":[39],"recently":[41],"naltrexone":[44,64,82,111,126,181],"drug":[46,142],"seeking":[47],"in":[48,71,88,93],"experimental":[49],"models":[50],"self-adminstration,":[53],"and":[54,75,130],"modulates":[55],"sensitized":[56],"locomotor":[57],"behaviour.":[58],"In":[59],"our":[60],"human":[61],"laboratory":[62],"models,":[63],"blunts":[65],"subjective":[67],"both":[72],"healthy":[73],"subjects":[74],"dependent":[77],"patients.":[78],"The":[79,144,175],"efficacy":[80],"to":[83,109,121,194],"increase":[84],"weeks":[85,166],"abstinence":[87,149],"amphetamine-dependent":[89],"patients":[90,116,171],"was":[91,148],"tested":[92],"placebo":[95,113,196],"controlled":[96],"trial.":[97],"Eighty":[98],"individuals":[99],"meeting":[100],"DSM":[101],"IV":[102],"criteria":[103],"were":[107,136],"randomized":[108],"either":[110],"or":[112,127],"treatment.":[114,168],"All":[115],"visited":[117],"clinic":[119],"weekly":[120,139],"receive":[122],"(50":[124],"mg":[125],"identical":[128],"placebo)":[129],"relapse":[131],"prevention":[132],"therapy.":[133],"Urine":[134],"samples":[135,163],"analysed":[137],"twice":[138],"illicit":[141],"use.":[143],"primary":[145],"outcome":[146],"measure":[147],"from":[150],"use,":[152],"as":[153],"measured":[154],"by":[155],"total":[157],"number":[158,187],"negative":[160,190],"urine":[162,191],"during":[164],"12":[165],"Overall,":[169],"55":[170],"(68.7%)":[172],"completed":[173],"study.":[174],"intention-to-treat":[176],"analysis":[177],"showed":[178],"group":[182,198],"had":[183],"significantly":[185],"higher":[186],"samples,":[192],"compared":[193],"treated":[197],"(p":[199],"1":[200],"Department":[201],"Clinical":[203],"Neuroscience,":[204],"Division":[205],"Psychiatry,":[207],"Karolinska":[208],"Institutet,":[209],"SE-17176":[210],"Stockholm,":[211],"Sweden":[212],"*johan.franck@ki.se":[213]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2528056154","counts_by_year":[],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-10-14T00:00:00"}
